TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in dermal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in testosterone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total ED length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Endothelial dysfunction measured by abnormal flow mediated dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount of Chest Catheter Drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric Volume (fasting and postprandial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Antral Contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Willingness to participate in the intervention trial
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent change in lumbar spine BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of wound size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of participants with severe OHSS
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in neurological condition related to the tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Experiencing at Least One Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Participation in working life
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: 28-day All-cause Mortality: Main Trial Population
Endpoint domain: Mortality/survival
Primary endpoint: 28-day All-cause Mortality: Moderate Chronic Kidney Disease Population
Endpoint domain: Mortality/survival
Primary endpoint: 28-day All-cause Mortality: COVID-19 Population
Endpoint domain: Mortality/survival
Primary endpoint: Daptomycin Transmembrane Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Technical Performance Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Invasive mould infections (IMIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with sustained clinical recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure of the syringe after inflation of the LMA cuff
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Influenza neutralizing antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in plasma L-methylfolate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time of regaining full enteral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of Patients with Myasthenia Gravis Score Increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Amplitude of Eyeblink Startle Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dykens Hyperphagia Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Procedural Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in body weight per participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants who achieve weight loss goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 12 months survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Percent of canal space occupied by debris
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACTH levels changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cortisol levels changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Growth hormone levels changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prolactin levels changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of PF-04950615
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Decay Half-Life (t1/2) of PF-04950615
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Solicited Injection-Site Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Termination From Treatment Due to a Suspected Adverse Drug Reaction (SADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Events (AEs) of Grade 3 or Higher Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Dental Pain measured using the Wong-Baker FACES Pain Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental Pain and Behavior measured using Face, Legs, Activity, Cry, Consolability (FLACC) Behavioral Pain Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calculated Central Venous Pressure (CVP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Retinal microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Functional status tests
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to first serious adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Sodium/Potassium Ratio in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: California Verbal and Learning Test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pathologic Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outpatient hospital visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: AOFAS Ankle-Hindfoot Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in KOOS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ankle re-injury rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in mental quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in physical quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: General cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Memory function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in net weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence rate of VAP and VAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Brief Pain Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Chronic Pain Acceptance Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: discontinuation of medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean muscle attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung nodule detection sensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients' file without severe error
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III score at 4-week follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III score at 8-week follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Plasmatic level of interleukins IL6 and IL10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complications in women
Endpoint domain: Adverse events/effects
Primary endpoint: Morphologic Evolution of Intracranial Atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average total nasal symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Objectively Monitored Sedentary Behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anterior chamber deep (ACD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lens thickness (LT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pupillary diameter (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal hysteroscopic findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients with serum bilirubin ≤ 300µmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in capillary blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total case time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent Change From Baseline in Enumeration of Circulating Tumor Cells (CTCs) in Whole Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent Change From Baseline in Gene Expression of Platelet-Derived Growth Factor Receptor Alpha (PGDFRα) and PGDFR Beta (β) in Tumor Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent Change From Baseline in Gene Expression of PDGF A, PDGF B, PDGF C, and PDGF-D Canonical Ligands in Tumor Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: oral mucosal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hamilton Depression Rating Scale (HDRS) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: autonomic nervous system activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: frequency of self-management activities
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of Recurrences of Prostate Cancer
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Grade 3 or Higher Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Erectile Function
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Change in Urinary Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in hepatic and visceral adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fugl Meyer Motor Assessment Scale (FMMAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total and First Phase of Insulin Secretion (Insulinogenic Index and Stumvoll Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin Sensitivity (Matsuda Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Microorganism reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Receipt of a colorectal cancer screening test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: New acute diarrhea episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cell-mediated immune response to varicella
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain Perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IAUC postprandial blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean patient rounding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean rounding proportion spent at the patient's bedside
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean rounding proportion spent on various rounding activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Advanced AD Pattern Flortaucipir PET Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With AD Pattern Flortaucipir PET Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reliability of the non-invasive ThM device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceptual organization index - Matrix reasoning subtest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perceptual organization index - Block design subtest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Processing speed index - Coding subtest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Working memory index - Digit span subtest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Child's relative reinforcing value of food versus parent-child interaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child's maximum schedule reached for food (food reinforcement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child's maximum schedule reached for parent-child interaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality after first ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Functional disability after stroke
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Health-related quality of life after stroke
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cortical index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: X-ray results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell-associated total HIV-1 DNA in CD4 T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Viral copies in plasma and culture supernatants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ex vivo HIV-1 infection tests on CD4 T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Parasitological cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in ODI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Appropriate Thromboprophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unplanned clinic or hospital visits requiring IV treatment for heart failure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: serum concentrations of ADAb anti adalimumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Tau/P-Tau level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical diagnosis of preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Percent of patients with evidence of new lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rates of falls
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Peabody Developmental Motor Scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: White blood cells (WBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validated outcome score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hematology parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mobility of the jaw
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug-eluting stent thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first excisional polypectomy post IRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to first excisional polypectomy post IPAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Persistent wheeze
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of grade 3+ adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Time until treatment-related grade 3+ toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Time to progression according to RECIST version 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients That Achieve a Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ototoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Endocrine dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Neurocognitive Effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety at 6 weeks follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Change in OBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with AF receiving guideline-concordant stroke prevention therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assessment of health outcomes in HD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of anti-TNF α agent candidates fulfilling the reimbursement guideline
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of anti-TNF α agent candidates based on clinical judgement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Composite measure of MACCEs
Endpoint domain: Mortality/survival
Primary endpoint: Plasma concentration of BAY86-9766
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of M17 and M11
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of Gemcitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of dFdU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events, or abnormal parameters as a measure of safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Total Amount of Opioid Used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants on Tocilizumab
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: probability of target attainment (fT>MIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: probability of target attainment (fAUC/MIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: probability of toxicity threshold attainment (minimal trough concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of portal hypertensive complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10% decrease of virtual hepatic venous pressure gradient (HVPG) from baseline level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epidural Pressure Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tiredness (PIPER Score)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Successful Radiographic Fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Scheduled appointments attended
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Perceived quality of medical care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose Variability assessed by 3 day SMBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bladder Injury Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes